These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37714762)

  • 1. Practical Guidance on Establishing a Molecular Testing Pathway for Alterations in Homologous Recombination Repair Genes in Clinical Practice for Patients with Metastatic Prostate Cancer.
    Schostak M; Bradbury A; Briganti A; Gonzalez D; Gomella L; Mateo J; Penault-Llorca F; Stenzinger A; Wyatt AW; Bjartell A
    Eur Urol Oncol; 2024 Jun; 7(3):344-354. PubMed ID: 37714762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world homologous recombination repair mutation testing in metastatic castration-resistant prostate cancer in the USA, Europe and Japan.
    Leith A; Ribbands A; Kim J; Last M; Barlow S; Yang L; Ghate SR
    Future Oncol; 2022 Mar; 18(8):937-951. PubMed ID: 35043687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer.
    Gonzalez D; Mateo J; Stenzinger A; Rojo F; Shiller M; Wyatt AW; Penault-Llorca F; Gomella LG; Eeles R; Bjartell A
    J Pathol Clin Res; 2021 Jul; 7(4):311-325. PubMed ID: 33630412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations.
    Shore N; Oliver L; Shui I; Gayle A; Wong OY; Kim J; Payne S; Amin S; Ghate S
    J Urol; 2021 Apr; 205(4):977-986. PubMed ID: 33332152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians.
    Merseburger AS; Waldron N; Ribal MJ; Heidenreich A; Perner S; Fizazi K; Sternberg CN; Mateo J; Wirth MP; Castro E; Olmos D; Petrylak DP; Chowdhury S
    Eur Urol; 2021 Apr; 79(4):519-529. PubMed ID: 33494937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA Repair in Prostate Cancer: Biology and Clinical Implications.
    Mateo J; Boysen G; Barbieri CE; Bryant HE; Castro E; Nelson PS; Olmos D; Pritchard CC; Rubin MA; de Bono JS
    Eur Urol; 2017 Mar; 71(3):417-425. PubMed ID: 27590317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
    Antonarakis ES; Gomella LG; Petrylak DP
    Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value.
    Fan Y; Liu Z; Chen Y; He Z
    Adv Ther; 2024 Jun; 41(6):2196-2216. PubMed ID: 38767824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients With Advanced Prostate Cancer From Latin America: Challenges and Future Approaches.
    Manneh R; Verson CA; Martin A; Delgado A; Isaacsson Velho PH; Manduley A; Tejado L; Rodríguez Y; Vargas C; Barata PC
    JCO Precis Oncol; 2024 May; 8():e2300628. PubMed ID: 38748947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
    de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K
    Lancet Oncol; 2021 Sep; 22(9):1250-1264. PubMed ID: 34388386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homologous recombination repair gene mutations in Chinese localized and locally advanced prostate cancer patients.
    Jiang X; Hu X; Gu Y; Li Y; Jin M; Zhao H; Gao R; Huang Z; Lu J
    Pathol Res Pract; 2021 Aug; 224():153507. PubMed ID: 34102435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of homologous recombination repair mutations in prostate cancer.
    Cresta Morgado P; Mateo J
    Prostate; 2022 Aug; 82 Suppl 1():S45-S59. PubMed ID: 35657156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olaparib for the treatment of metastatic prostate cancer.
    Dror CM; Wyatt AW; Chi KN
    Future Oncol; 2021 Jul; 17(19):2413-2429. PubMed ID: 33769071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: The multi-institutional observational ZENSHIN study.
    Uemura H; Oya M; Kamoto T; Sugimoto M; Shinozaki K; Morita K; Koto R; Takahashi M; Nii M; Shin E; Nonomura N
    Cancer Med; 2023 Mar; 12(5):5265-5274. PubMed ID: 36358026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.
    Gillessen S; Attard G; Beer TM; Beltran H; Bjartell A; Bossi A; Briganti A; Bristow RG; Chi KN; Clarke N; Davis ID; de Bono J; Drake CG; Duran I; Eeles R; Efstathiou E; Evans CP; Fanti S; Feng FY; Fizazi K; Frydenberg M; Gleave M; Halabi S; Heidenreich A; Heinrich D; Higano CTS; Hofman MS; Hussain M; James N; Kanesvaran R; Kantoff P; Khauli RB; Leibowitz R; Logothetis C; Maluf F; Millman R; Morgans AK; Morris MJ; Mottet N; Mrabti H; Murphy DG; Murthy V; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Parker C; Poon DMC; Pritchard CC; Reiter RE; Roach M; Rubin M; Ryan CJ; Saad F; Sade JP; Sartor O; Scher HI; Shore N; Small E; Smith M; Soule H; Sternberg CN; Steuber T; Suzuki H; Sweeney C; Sydes MR; Taplin ME; Tombal B; Türkeri L; van Oort I; Zapatero A; Omlin A
    Eur Urol; 2020 Apr; 77(4):508-547. PubMed ID: 32001144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Prognostic Significance of Homologous Recombination Repair Pathway Alterations in Metastatic Hormone Sensitive Prostate Cancer.
    Lee AM; Saidian A; Shaya J; Nonato T; Cabal A; Randall JM; Millard F; Stewart T; Rose B; Tamayo P; McKay RR
    Clin Genitourin Cancer; 2022 Dec; 20(6):515-523. PubMed ID: 35871039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer.
    Carr TH; Adelman C; Barnicle A; Kozarewa I; Luke S; Lai Z; Hollis S; Dougherty B; Harrington EA; Kang J; Saad F; Sala N; Thiery-Vuillemin A; Clarke NW; Hodgson D; Barrett JC
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer Harboring Somatic or Germline Homologous Recombination Repair Gene Mutations: Phase II Single-Arm Trial.
    Jain R; Kumar A; Sharma A; Sahoo RK; Sharma A; Seth A; Nayak B; Shamim SA; Kaushal S; Kp H; Das CJ; Batra A
    JMIR Res Protoc; 2024 Apr; 13():e54086. PubMed ID: 38453159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
    Fujimoto N; Harada K; Shiota M; Tomisaki I; Minato A; Nagata Y; Kimuro R; Harada M; Fujisawa M
    Anticancer Res; 2021 Oct; 41(10):4687-4695. PubMed ID: 34593416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.